Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29885821 | 1.00 | CYP3A4 (0.48) | CYP3A4ESRRAL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL4350401 | 0.84 | CYP1A1 (0.47) | CYP3A4ESRRAL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL29775476 | 0.84 | CYP1A1 (0.47) | CYP3A4ESRRAL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL7812572 | 0.82 | ALDH1A1 (0.46) | CYP3A4ESRRAL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL16428890 | 0.82 | ALDH1A1 (0.48) | CYP3A4L3MBTL1RAB9AALDH1A1NPSR1 | |
| SCHEMBL580616 | 0.82 | ALDH1A1 (0.48) | CYP3A4L3MBTL1RAB9AALDH1A1NPSR1 | |
| SCHEMBL30679140 | 0.82 | ALDH1A1 (0.48) | CYP3A4L3MBTL1RAB9AALDH1A1NPSR1 | |
| SCHEMBL3903635 | 0.81 | CA2 (0.49) | L3MBTL1RAB9AALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL10451549 | 0.81 | MEN1 (0.53) | CYP3A4L3MBTL1RAB9AALDH1A1NPSR1 | |
| SCHEMBL8161648 | 0.81 | ALDH1A1 (0.44) | CYP3A4ESRRAL3MBTL1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554378-A | Non-metallocene catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2025090541-A1 | COVALENT DEGRADERS OF ONCOGENIC TRANSCRIPTION FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4373814-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117651699-A | Compounds and compositions for the treatment of coronavirus related diseases | 诺华股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117486808-A | Novel preparation method of letromycin key intermediate | 北京康立生医药技术开发有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116554378-A | Non-metallocene catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-5877191-A | ANTIINFLAMMATORY AGENT; ANALGESICS; ANTIHISTAMINES; EMESIS | MERCK & CO., INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1998017660-A1 | PHENYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0367671-B1 | NOVEL BETA-D-PHENYLTHIOXYLOSIDES, THEIR METHOD OF PREPARATION AND THEIR USE AS PHARMACEUTICALS | FOURNIER INDUSTRIE ET SANTE (FR) | 1993-07-28 | — | — | EP | disclosed |
| US-4960758-A | Antithrombotics | FOURNIER INNOVATION ET SYNERGIE (FR) | 1990-10-02 | — | — | US | disclosed |
| EP-0367671-A2 | Novel beta-D-phenylthioxylosides, their method of preparation and their use as pharmaceuticals | FOURNIER INDUSTRIE ET SANTE (FR) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | CYP3A4 3111/4885ESRRA 2595/4885L3MBTL1 1658/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | CYP3A4 116/4885ESRRA 3541/4885L3MBTL1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.